Multiple micro-bypass stents lower IOP

Article

Multiple micro-bypass stents with concurrent cataract surgery lowers IOP to less than 15 mmHg in patients with open-angle glaucoma (OAG) and cataract.

Multiple micro-bypass stents with concurrent cataract surgery lowers IOP to less than 15 mmHg in patients with open-angle glaucoma (OAG) and cataract.

A team led by Dr Graham W. Belovay, at a private practice, Mississauga, Ontario, Canada, completed a comparative case series on 53 eyes of 47 patients with OAG. Of the eyes studied, 28 had two stents implanted and 25 had three stents implanted.

Each patient was followed up for one year and efficacy measures included intraocular pressure (IOP) and topical ocular hypotensive medication use. The safety assessment consisted of complications and corrected distance visual acuity (CDVA).

Overall mean one-year postoperative IOP was 14.3 mmHg, which was significantly lower than the overall preoperative IOP. Target IOP was achieved in a high proportion of eyes and there were 83% of eyes who experienced a reduction in topical ocular hypotensive medication one-year postoperatively.

The three-stent group required significantly fewer medications than the two-stent group at one year.

The abstract can be found in the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.